NENC Provider Collaborative’s Post

Thoughts on this? >> Sanofi and Regeneron’s Dupixent wins EU nod in COPD ahead of September PDUFA >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharmaceutical #pharma #productmarketing

Thoughts on this? >> Sanofi and Regeneron’s Dupixent wins EU nod in COPD ahead of September PDUFA >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #healthcare #pharma #pharmaceutical #biotech

Thrilled to have spoken at the 22nd annual conference of the Pharmaceutical Society of Israel today! 🌟 My talk, "Alopecia Areata: The Patient's Journey, Disease Burden, and New Treatments," aimed to shed light on the personal and societal impacts of this challenging condition and discuss groundbreaking advancements in its treatment. Engaging with fellow professionals passionate about improving patient care is always enriching. I’m grateful for the thoughtful discussions and the opportunity to contribute to our collective understanding and management of alopecia areata. #PharmaceuticalSocietyofIsrael #AlopeciaAreata #PatientCare #MedicalConference

2023 saw the highest number of drug #approvals by FDA in over 20 years, including numerous #innovative therapies for #rarediseases. Learn more on how Hansa Biopharma remains committed to working with multiple stakeholders to ensure we advance the science of and deliver innovative new treatments to address the unmet need in rare disease. https://lnkd.in/daEdhuu6

HUMIRA still holds 99% share in total volume. Even when most prescribed biosimilars all launched with a low WAC, biosimilars account for only 1% of adalimumab and ~2% of new starts across indications. Only 1 in 3 patients prescribed an adalimumab biosimilar managed to fill in the 30 days following their first attempt. Written Humira prescriptions outnumbered biosimilars by a factor of 46 to 1 in November 2023 The data is till Nov 2023, and CVS removed Humira as of yesterday; some impact might be coming, but 99% is still huge. https://lnkd.in/er_w8_6n

EUFOREA is thrilled to announce the release of its new patient guide on Chronic Rhinosinusitis (including CRSwNP/Nasal Polyp Syndrome)! Developed by EUFOREA, this comprehensive guide provides patients with essential information to navigate their CRSwNP journey effectively. Inside the guide, you'll find: 👃 An overview of common symptoms associated with CRSwNP 💊 A breakdown of different treatment options, including new therapies like biologics, with pros and cons for each 🔍 Insights into diagnostic tests used to diagnose the condition 📝 Handy tips for preparing for doctor's appointments to maximize your time and ensure effective communication with your healthcare provider Empower yourself with knowledge and take control of your CRSwNP management journey. Download your copy of the patient guide today: https://lnkd.in/ekfScp4r #CRSwNP #PatientEmpowerment #Healthcare #EUFOREA #NasalPolyps #ChronicRhinosinusitis

#DYK that biosimilar medicines are potentially less expensive than original biologics, whilst having the same effectiveness? Meet Cory Wohlbach, who is responsible for steering Teva’s new biosimilar products through the regulatory approval process. Here he explains what biosimilars are and how they are advancing more treatment options for patients. #Tevapharm #Biosimilars #AccesstoHealthcare #OurPeople

#PharmaSynergyRx 2025 – Early Registration Now Open! Take advantage of our two promo weeks, offering you an additional 10% off on top of the Early Bird discount. The promo period starts on Monday, June 3. Use the promo code "PharmaSynergyRX25" to get an additional 10% off on top of the Early Bird discount. Hurry, this special promo code expires on June 14, 2024. Is your portfolio within Rx/Primary & Complex Generics, VAMs, Biosimilars, Specialty, Hospital products, Late-stage development assets, or Orphan medicines? Then don't miss this opportunity! For registration details, please visit our website at https://lnkd.in/euhQ26RG or get in touch via [email protected] Ask for more details at [email protected] #Primary #Niche #Branded #HybridGenerics #Value_Added_Medicines (#VAMs) #Biosimilars #Specialty #HospitalProducts #Legacyproducts #Orphandrugs #NewChemicalEntities #NOT_JUST_ANOTHER_EVENT #PRODUCT_FOCUSED_PARTNERING_EVENT

Strides Pharma Secures USFDA Approval for Theophylline Extended-Release Tablets https://lnkd.in/d4Z2cUdd #StridesPharma #USFDAApproval #TheophyllineTablets #GenericDrugs #RespiratoryHealth Strides Pharma Science Ltd has secured USFDA approval for its generic version of Theophylline Extended-Release Tablets, marking a significant milestone for the company. Available in 300 mg and 450 mg strengths, this new generic option offers a cost-effective solution for managing chronic respiratory conditions such as asthma. With this approval, Strides Pharma aims to expand its market presence and provide patients with affordable, high-quality medication alternatives.

In this latest K-Cast series, “Advancing Healthcare With Prescription Drug Therapeutics,” experts discuss insurance coverage considerations for prescription digital therapeutics and how payers and providers can work together to ensure optimal patient outcomes. Tune in here: https://bit.ly/4bt3Dqs #ManagedCare #HealthTech Mahsa Salsabili